2/4
08:30 am
apre
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Low
Report
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
1/29
01:02 pm
apre
Aprea Therapeutics (NASDAQ:APRE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock, down previously from $5.00.
Low
Report
Aprea Therapeutics (NASDAQ:APRE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock, down previously from $5.00.
1/29
08:27 am
apre
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
High
Report
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
1/29
08:25 am
apre
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
High
Report
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
1/23
05:06 am
apre
Aprea Therapeutics (NASDAQ:APRE) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Aprea Therapeutics (NASDAQ:APRE) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/15
07:46 am
apre
Aprea Therapeutics (NASDAQ:APRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Aprea Therapeutics (NASDAQ:APRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
12/18
12:14 pm
apre
Aprea Therapeutics (NASDAQ:APRE) had its price target lowered by analysts at HC Wainwright from $20.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Aprea Therapeutics (NASDAQ:APRE) had its price target lowered by analysts at HC Wainwright from $20.00 to $5.00. They now have a "buy" rating on the stock.
12/18
08:30 am
apre
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
Low
Report
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
12/9
08:30 am
apre
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
High
Report
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
11/12
08:43 am
apre
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update [Yahoo! Finance]
Medium
Report
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update [Yahoo! Finance]
11/12
08:30 am
apre
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
Medium
Report
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update